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In our recent article [1], we did not declare the patent rights related to stampidine technology. Since they may potentially be viewed as non-financial competing interests despite the fact our employer is a non-profit public charity, we are now providing the following supplemental information:
FMU, AOV and HET are employees of Parker Hughes Institute, which has applied for a patent for the use of stampidine in the treatment of haemorrhagic fever. Parker Hughes Institute currently holds patents for the use of stampidine in other clinical conditions, with FMU listed as an inventor.
